09:33 AM EDT, 07/30/2025 (MT Newswires) -- NetraMark Holdings ( AINMF ) , an artificial intelligence company, and Pentara Corporation, a company offering clinical data analysis services to the pharmaceutical and biotechnology industries, said on Wednesday that they signed an agreement to detect anomalous site and participant behavior and "safeguard clinical trial integrity."

NetraMark ( AINMF ), in collaboration with Pentara, will co-brand and launch a novel site intelligence tool as part of a joint initiative "to enhance clinical trial integrity through advanced AI-driven anomaly detection."

A statement noted that the framework identifies site-level integrity and anomalous risks using only pre-randomization data.

"We are excited to partner with NetraMark ( AINMF ), which focuses on the responsible use of AI in clinical trials, and the implementation of regulatory-aligned AI strategies that provide data-driven insights to guide success throughout a trial," said Pentara Corporation's Chief Executive Officer, Suzanne Hendrix. "Applying this innovative technology demonstrates our commitment to providing high-quality, efficient solutions to our clients that accelerate medical research."

Price: 1.46, Change: -0.01, Percent Change: -0.68